FEMY - Femasys Inc. Stock Price, Fair Value and News

$1.09-0.01 (-0.91%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FEMY Price Action

Last 7 days

-8.4%

Last 30 days

11.2%

Last 90 days

-5.2%

Trailing 12 Months

22.5%

FEMY RSI Chart

FEMY Valuation

Market Cap

25.0M

Price/Earnings (Trailing)

-1.38

Price/Sales (Trailing)

19.8

EV/EBITDA

-0.96

Price/Free Cashflow

-1.38

FEMY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FEMY Fundamentals

FEMY Revenue

Revenue (TTM)

1.3M

Rev. Growth (Yr)

127.09%

Rev. Growth (Qtr)

150.54%

FEMY Earnings

Earnings (TTM)

-18.1M

Earnings Growth (Yr)

-35.33%

Earnings Growth (Qtr)

-15.46%

FEMY Profitability

EBT Margin

-1467.27%

Return on Equity

-303.25%

Return on Assets

-116.16%

Free Cashflow Yield

-72.54%

FEMY Investor Care

Shares Dilution (1Y)

5.77%

Diluted EPS (TTM)

-0.81

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.0M	950.1K	1.3M	0
2023	1.2M	1.2M	1.1M	1.1M
2022	1.2M	1.1M	1.2M	1.2M
2021	1.1M	1.1M	1.1M	1.2M
2020	0	0	0	1.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Femasys Inc.

Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

CEO	Ms. Kathy Lee-Sepsick
WEBSITE	femasys.com
SECTOR	Healthcare
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	34

Femasys Inc. Frequently Asked Questions

What is the ticker symbol for Femasys Inc.? What does FEMY stand for in stocks?

FEMY is the stock ticker symbol of Femasys Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Femasys Inc. (FEMY)?

As of Fri Dec 20 2024, market cap of Femasys Inc. is 24.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FEMY stock?

You can check FEMY's fair value in chart for subscribers.

Is Femasys Inc. a good stock to buy?

The fair value guage provides a quick view whether FEMY is over valued or under valued. Whether Femasys Inc. is cheap or expensive depends on the assumptions which impact Femasys Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FEMY.

What is Femasys Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, FEMY's PE ratio (Price to Earnings) is -1.38 and Price to Sales (PS) ratio is 19.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FEMY PE ratio will change depending on the future growth rate expectations of investors.